In recent years, efforts to enhance international payer collaboration and the willingness to exchange expertise and knowledge have increased substantially. The need for international exchange…
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Joint statement of the Beneluxa Initiative and the Nordic Pharmaceutical Forum
Beneluxa Statement on high cost SMA treatments
Pharmacological treatments of Spinal Muscular Atrophy (SMA) have expanded across the full spectrum of the disease. Onasemnogene abeparvovec targets disease in patients with SMA who are presymptomatic…
Beneluxa joint assessment Zolgensma completed
The Beneluxa Initiative announces it has successfully completed another joint effort; the assessment of Zolgensma (onasemnogene abeparvovec) for Spinal Muscular Atrophy (SMA). Following the…